UNICA IRIS Institutional Research Information System

ORIGA, RAFFAELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 106.848
NA - Nord America 5.358
AS - Asia 1.043
SA - Sud America 16
AF - Africa 14
OC - Oceania 6
Totale 113.285
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 105.283
US - Stati Uniti d'America 5.324
CN - Cina 584
SE - Svezia 452
UA - Ucraina 440
SG - Singapore 236
DE - Germania 222
FI - Finlandia 147
GB - Regno Unito 140
VN - Vietnam 72
CA - Canada 34
FR - Francia 34
IN - India 33
RU - Federazione Russa 22
BE - Belgio 21
IR - Iran 16
PK - Pakistan 15
BR - Brasile 14
NL - Olanda 13
TR - Turchia 13
MY - Malesia 12
TH - Thailandia 11
IQ - Iraq 10
RO - Romania 10
SI - Slovenia 10
ES - Italia 7
ID - Indonesia 7
AT - Austria 6
BG - Bulgaria 6
KR - Corea 6
AU - Australia 5
CH - Svizzera 5
EG - Egitto 5
IE - Irlanda 5
IL - Israele 5
LT - Lituania 5
GR - Grecia 4
HU - Ungheria 4
TW - Taiwan 4
BD - Bangladesh 3
CY - Cipro 3
CZ - Repubblica Ceca 3
JO - Giordania 3
PL - Polonia 3
JP - Giappone 2
KE - Kenya 2
LU - Lussemburgo 2
MA - Marocco 2
PT - Portogallo 2
AZ - Azerbaigian 1
CG - Congo 1
CI - Costa d'Avorio 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
HK - Hong Kong 1
KH - Cambogia 1
LK - Sri Lanka 1
MT - Malta 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 113.285
Salva come PNG Salva come JPEG
Città #
Cagliari 101.158
Uta 2.924
Woodbridge 679
Fairfield 635
Chandler 526
Boardman 364
Houston 359
Nyköping 352
Ashburn 303
Ann Arbor 293
Wilmington 265
Seattle 213
Cambridge 209
Jacksonville 184
Dearborn 178
Santa Clara 114
Singapore 108
Boston 102
Rome 100
Milan 96
Shanghai 95
Nanjing 87
Beijing 84
Helsinki 75
Dong Ket 64
San Diego 54
Guangzhou 36
Naples 36
Hebei 27
Redwood City 27
Sassari 26
Shenyang 23
London 22
New York 22
Bari 20
Brussels 20
Toronto 20
Changsha 19
Nanchang 19
Turin 19
Florence 18
Mountain View 17
Jiaxing 16
Munich 16
Hefei 15
Jinan 14
Livorno 14
Los Angeles 14
Tianjin 14
Seregno 13
Catania 10
Gavirate 10
Gurgaon 10
Norwalk 10
Orange 10
Pune 10
Kunming 9
Ljubljana 9
Padova 9
Quartu Sant'Elena 9
Renton 9
Verona 9
Genoa 8
Palermo 8
Taranto 8
Washington 8
Zhengzhou 8
Bangkok 7
Bologna 7
Kuala Lumpur 7
Atlanta 6
Bucharest 6
Hounslow 6
Messina 6
Millbury 6
Shenzhen 6
Sofia 6
Stockholm 6
Taizhou 6
Vienna 6
Wuhan 6
Amsterdam 5
Augusta 5
Brescia 5
Chicago 5
Dublin 5
Ercolano 5
Krefeld 5
Lafayette 5
Ningbo 5
Paris 5
Acton 4
Alessandria 4
Auburn Hills 4
Carlsbad 4
Falls Church 4
Guwahati 4
Indiana 4
Kilburn 4
Lecce 4
Totale 110.435
Salva come PNG Salva come JPEG
Nome #
Thalassemia major between liver and heart: Where we are now 3.974
Current growth patterns in children and adolescents with thalassemia major 2.887
A decisional algorithm to start iron chelation in patients with beta thalassemia 2.816
A genetic score for the prediction of beta-thalassemia severity 2.783
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia 2.616
Deferasirox and children: From clinical trials to the real world 2.406
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias 2.260
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation 2.146
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia 2.077
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.053
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015 1.995
Thalassemia major: who is afraid of serum ferritin below 500 μg/l? 1.939
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia. 1.926
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment 1.891
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study 1.877
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia 1.812
Investigating the Alpha 1Ncol mutation 1.784
null 1.759
Hematological phenotypes in children according to the α-globin genotypes 1.685
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.642
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.565
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia 1.458
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major 1.456
Deferasirox: pharmacokinetics and clinical experience 1.365
β-Thalassemia 1.356
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major 1.294
A complicated disease: What can be done to manage thalassemia major more effectively? 1.269
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia 1.260
Alpha-Thalassemia 1.238
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 1.231
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload 1.221
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major 1.201
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA 1.128
Prospettive in Pediatria 1.096
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron 1.088
Clinical and molecular analysis of haemoglobin H disease in Sardinia: Haematological, obstetric and cardiac aspects in patients with different genotypes 1.084
Combined therapy with deferiprone and desferrioxamine in thalassemia major 1.013
null 1.009
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major 972
Lack of heart iron overload in patients with thalassemia intermedia. 951
Onset of cardiac iron loading in pediatric patients 939
null 886
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up 827
Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant 823
Urinary hepcidin in thalassemic syndromes 816
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia 786
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up 764
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major 753
Pregnancy in Thalassemia 731
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia 699
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox 692
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 687
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 686
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study 674
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA 667
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis 651
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 651
Genetic basis, pathophysiology and diagnosis 634
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study 633
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (beta)-Thalassemia: Interim Results 629
Changing patterns of thalassaemia in Italy: a WebThal perspective. 629
DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION) 625
null 618
Retrospective evaluation of different iron chelators on cardiac T2* 611
Pathophysiology of beta thalassaemia 610
Beta-thalassemia 608
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions 596
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment 594
null 589
Beta-Thalassemia. 586
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects 580
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 579
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias 578
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) 563
Pregnancy and β-thalassemia: An Italian multicenter experience 552
Lack of correlation between serum ferritin and liver iron concentration in beta-zero thalassemia intermedia 543
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021 540
null 539
Cholelithiasis in thalassemia major 539
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5] 528
Neutropenia in patients with thalassemia major. 523
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial 511
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 509
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 508
GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia 506
Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey 504
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 493
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm 482
Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC) 482
Prima e dopo la splenectomia: terapia combinata in un paziente con compromissione cardiaca secondaria all'accumulo di ferro. 468
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations 467
null 435
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 433
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study 432
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 426
Densità minerale ossea e rischio di frattura nella _ talassemia major 410
The Management of Endocrine Complications in Patients with Haemoglobinopathies: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) 405
Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector 405
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies" 401
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload 393
Totale 104.011
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.419
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 149.419
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.958 0 0 0 0 0 5.237 2.577 631 364 266 371 512
2020/202123.558 539 683 777 8.498 5.556 1.885 1.322 973 413 836 991 1.085
2021/20228.150 715 540 416 589 916 841 360 487 508 817 1.092 869
2022/202311.368 1.034 1.395 1.223 756 1.008 953 471 1.504 723 737 1.026 538
2023/202413.514 644 557 523 952 1.107 2.317 2.438 854 655 1.002 1.156 1.309
2024/202519.152 4.381 4.815 4.101 3.125 1.580 1.150 0 0 0 0 0 0
Totale 113.819